Although small molecules or antibodies targeting TGFβR have the potential to impair pro-tumor immunity by interfering with the differentiation and functions of Tregs, they do not selectively discriminate between specific cell lineages, thus resulting in indiscriminate shutdown of TGFβ signaling. The gene discussed is TGFB1; the disease is neoplasm.